Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings Corp has demonstrated impressive financial growth, achieving a remarkable 65% year-over-year increase in core exome/genome revenue for Q3, resulting in both topline and bottom-line performance surpassing expectations. The company has also raised its 2025 revenue guidance to $425-428 million, reflecting a solid annual growth projection of 39%-40%, supported by a significant increase in average selling prices to $3,850 per test, up 23% year-over-year. Additionally, the strategic realignment to target pediatric neurologists and the expansion of its offerings to over 30 biopharma programs in rare diseases further enhance GeneDx's market position and long-term growth potential.

Bears say

GeneDx Holdings Corp is projected to experience a significant cash burn of approximately $2 million per quarter, raising concerns about its financial sustainability. The company faces a critical risk related to third-party payer reimbursement, as inadequate payment structures or renegotiations could hinder commercial success, exacerbated by a high denial rate of 45% for tests despite being contracted with around 80% of health plans. Additionally, the reliance on a limited number of sales representatives and the potential disruptions in data and workflow services further contribute to the negative outlook regarding the company's operational effectiveness and financial health.

WGS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 7 analysts, WGS has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $120.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $120.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.